World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 12 December 2020
Main ID:  NCT00001964
Date of registration: 18/01/2000
Prospective Registration: No
Primary sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Public title: Combination Therapy of Severe Aplastic Anemia
Scientific title: Treatment of Severe Aplastic Anemia With Combined Immunosuppression: Antithymocyte Globulin (ATG) and Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF)
Date of first enrolment: December 2, 1999
Target sample size: 104
Recruitment status: Completed
Study type:  Interventional
Study design:  Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 2
Countries of recruitment
United States
Name:     Neal S Young, M.D.
Affiliation:  National Heart, Lung, and Blood Institute (NHLBI)
Key inclusion & exclusion criteria


Only patients with SAA will be admitted, defined as:

Bone marrow cellularity less than 30%.

At least two of the following blood count findings: absolute granulocyte count less than
500/mm(3); platelet count less than 20,000/mm(3); reticulocyte count less than

Age greater than or equal to 1 years.

Weight greater than 12 kg.


Serum creatinine greater than 2 mg/dl or estimated creatinine clearance less than 40

Underlying carcinoma, recent history of radiation or chemotherapy.

Current pregnancy or unwillingness to be treated with oral contraceptives.

Inability to comprehend the investigational nature of the study.

Moribund status or concurrent hepatic, renal, cardiac, neurologic, or metabolic disease of
such severity that death within 7 to 10 days is likely.

Evidence of other etiology than AA for bone marrow failure, including positive clastogenic
stress cytogenetic assay for Fanconi anemia and marrow chromosome abnormalities typical of

Age minimum: 1 Year
Age maximum: 99 Years
Gender: All
Health Condition(s) or Problem(s) studied
Severe Aplastic Anemia
Drug: ATG
Drug: Cyclosporine A
Drug: MMF
Primary Outcome(s)
reduction in 24-month relapse [Time Frame: 24 months]
Secondary Outcome(s)
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history